Pacific Biosciences Of California (PACB) Net Equity Issued and Repurchased (2010 - 2023)

Pacific Biosciences Of California has reported Net Equity Issued and Repurchased for 13 years, with the latest figure at $189.2 million in Q1 2023.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $189.2 million in Q1 2023; TTM through Dec 2023 was $189.2 million, a N/A change from a year earlier, with the FY2023 full-year figure at $189.2 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased was $189.2 million for Q1 2023 at Pacific Biosciences Of California, up from $1.7 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $300.0 million in Q3 2021, with the low at $131000.0 in Q4 2019.
• Average Net Equity Issued and Repurchased over 4 years is $43.9 million, with a median of $3.0 million recorded in 2021.
• The sharpest annual moves came in 2019 and 2020: Net Equity Issued and Repurchased plunged 97.61% in 2019, then surged 24469.47% in 2020.
• Over 4 years, Net Equity Issued and Repurchased stood at $131000.0 in 2019, then soared by 24469.47% to $32.2 million in 2020, then sank by 94.76% to $1.7 million in 2021, then soared by 11128.49% to $189.2 million in 2023.
• The last three Net Equity Issued and Repurchased figures came in at $189.2 million (Q1 2023), $1.7 million (Q4 2021), and $300.0 million (Q3 2021), per Business Quant data.